Oscar Health CFO Blackley sells $595,125 in shares By Investing.com
Oscar Health CFO Richard Scott Blackley sold 18,750 shares of the company's Class A Common Stock for a total of $595,125 on August 18, 2026. This sale occurred as Oscar Health shares traded near their 52-week high, following strong financial results in Q2 2026 where the company surpassed analyst expectations for earnings and revenue. Despite positive performance, the stock saw a premarket decline, suggesting investor focus on future outlooks.
Oscar Health CFO Blackley sells $595,125 in shares By Investing.com
Oscar Health CFO Richard Scott Blackley sold 18,750 shares of the company's Class A Common Stock for over $595,000, with individual share prices ranging from $31.28 to $32.15. This insider sale occurs while Oscar Health shares are near their 52-week high, despite InvestingPro analysis suggesting the stock may be overvalued. The company recently reported strong Q2 2026 results, exceeding analyst expectations for both earnings and revenue, driven by improved medical-cost management and expense control.
Oscar Health, Inc. SEC Filing (Aug 10, 2026)
This article details an SEC Form 144 filing by Oscar Health, Inc. (OSCR) on August 10, 2026. The filing indicates a proposed sale of 116,666 shares of Class A common stock by former director Jeffery H. Boyd, acquired through a stock option exercise, with an aggregate market value of over $3.2 million. The transaction is set to occur on August 10, 2026, through Fidelity Brokerage Services LLC.
(OSCR) as a Liquidity Pulse for Institutional Tactics
The article analyzes Oscar Health Inc. Class A (NASDAQ: OSCR), indicating a weak near and mid-term sentiment despite a positive long-term outlook. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths and support/resistance levels for OSCR.
Oscar Health Stock And 2 Fast Growing US Companies Investors May Want To Watch
This article highlights three US companies—Oscar Health (OSCR), Dutch Bros (BROS), and Chime Financial (CHYM)—that have high growth potential and solid financial prospects, identified through a focused screener. Each company is discussed with its market position, recent performance, future outlook, and potential risks, making them interesting for investors looking beyond traditional inflation-sensitive stocks. The article suggests these companies warrant a closer look due to their strong growth forecasts and unique business models.
Oscar Health (NYSE: OSCR) swings to Q2 2026 profit after prior-year loss
Oscar Health (NYSE: OSCR) reported a significant return to profitability in Q2 2026, achieving a net income of $361.8 million, a substantial improvement from a loss of $228.4 million in the prior year. Total revenue for the quarter reached $4.88 billion, up 71% year-over-year, driven by increased membership which grew by approximately 46% to 3.0 million effectuated members. The company's Medical Loss Ratio (MLR) also improved, decreasing to 79.2% from 91.1% in Q2 2025, reflecting disciplined pricing strategies and favorable prior-period reserve development.
Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook
Oscar Health, Inc. (NYSE: OSCR) reported record financial results for the first half of 2026, including significant increases in total revenue and net income, and has raised its full-year 2026 financial guidance. The company's CEO, Mark Bertolini, attributed this success to superior operating performance, disciplined pricing, and a scalable technology platform, emphasizing its strong position in the accelerating individual healthcare market. Key metrics show improved medical loss ratio and SG&A expense ratio, reflecting effective cost management and underwriting.
Form 8K Oscar Health Inc For: 6 August By Investing.com
The article reports on an 8K filing by Oscar Health Inc. on August 6th. It mentions that Oscar Health Inc. (OSCR) experienced an 11.59% drop. The content is very brief, serving primarily as an announcement of the filing.
Oscar Health (NYSE: OSCR) posts record H1 profit, lifts 2026 guidance
Oscar Health (NYSE: OSCR) announced record profitability for the first half of 2026, reporting a net income of $1,040,804 thousand and an Adjusted EBITDA of $1,142,421 thousand. The company also turned around its Q2 2026 performance with a net income of $361,808 thousand, driven by improved medical loss ratio and SG&A expense ratio. Consequently, Oscar Health raised its full-year 2026 guidance for earnings from operations to $500–$700 million, while maintaining total revenue guidance.
(OSCR) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis for Oscar Health Inc. Class A (NASDAQ: OSCR), highlighting positive near-term sentiment within a long-term strength context. It details institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests compelling upside potential due to the absence of clear resistance above the current price.
(OSCR) Movement as an Input in Quant Signal Sets
This article analyzes Oscar Health Inc. Class A (NASDAQ: OSCR) using AI models, identifying weak near-term sentiment but strong long-term potential. It provides three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and resistance/support levels for informed trading decisions.
(OSCR) Movement as an Input in Quant Signal Sets
This article analyzes Oscar Health Inc. Class A (NASDAQ: OSCR) using AI models to generate trading strategies and multi-timeframe signal analysis. It highlights weak near-term sentiment but strong long-term potential, providing specific entry zones, targets, and stop losses for position trading, momentum breakout, and risk hedging strategies. The analysis also details support and resistance levels across different time horizons.
Form 4 Oscar Health Inc For: 13 July By Investing.com
This article provides a brief notification regarding the filing of a Form 4 for Oscar Health Inc. on July 13. It includes the company's stock symbol (OSCR) and its positive price performance, specifically a 1.72% increase. The content indicates that the information is primarily a regulatory announcement disseminated by Investing.com.
Oscar Health (OSCR) director William Gassen receives 684 deferred stock units
Oscar Health director William Gassen was granted 684 deferred stock units (DSUs) on July 9, 2026, as compensation instead of cash board retainer fees. Each DSU, valued at $31.20, represents one share of Class A common stock and is 100% vested at grant. Following this transaction, Gassen directly holds 7,071 DSUs.
Oscar Health (OSCR) director Sid Sankaran receives 858 deferred stock units in lieu of cash
Oscar Health director Sid Sankaran received 858 deferred stock units (DSUs) on July 9, 2026, as compensation for his board service, elected in lieu of cash retainers. Each DSU represents one share of Class A common stock, valued at $31.20, and is 100% vested on the grant date. Following this transaction, Sankaran directly holds 2,061 DSUs, which will be settled in cash or shares within 45 days of a triggering event such as termination of service or a change in control.
Form 4 Oscar Health Inc For: 13 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Oscar Health Inc. on July 13. It includes a brief mention of Oscar Health's stock performance and contains a standard investment news layout with market data, news headlines, and advertising. The content primarily serves as a placeholder for the actual Form 4 details, which are not provided in the snippet.
Oscar Health (OSCR) director David Plouffe receives 681 deferred stock units as fee
Oscar Health director David Plouffe was granted 681 deferred stock units on July 9, 2026, as board compensation. These units, valued at $31.20 each, replaced cash retainer payments and are fully vested upon grant. Following this transaction, Plouffe directly holds 7,535 deferred stock units.
Oscar Health (OSCR) Is Up 9.1% After ACA Growth And Insider Sales Activity Has The Bull Case Changed?
Oscar Health (OSCR) has experienced a 9.1% stock increase, driven by strong revenue growth and expanded exposure to the Affordable Care Act (ACA) market. Despite a recent insider share sale, the company's investment narrative continues to focus on converting its tech-focused ACA model into durable profitability. A key challenge remains managing medical costs and regulation, as analysts have mixed views on its valuation and profitability outlook.
(OSCR) Movement as an Input in Quant Signal Sets
This article analyzes Oscar Health Inc. Class A (NASDAQ: OSCR) using AI models, identifying strong sentiment across all horizons and significant upside potential as no resistance levels remain above the current price. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss parameters, alongside multi-timeframe signal analysis to guide investors.
(OSCR) Movement as an Input in Quant Signal Sets
This article provides an analysis of Oscar Health Inc. Class A (NASDAQ: OSCR) using AI models, highlighting strong sentiment across all horizons and compelling upside potential due to the absence of resistance levels above the current price. It presents three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report emphasizes real-time entry and exit signals, risk-reward ratios, and personalized alerts available through a free account registration.
Oscar Health CEO Bertolini sells $35.7 million in company stock
Oscar Health CEO Mark T Bertolini sold over $35.7 million worth of company stock across several transactions on June 29 and June 30, 2026, to cover tax withholding obligations from vested performance stock units. The sales involved a total of 1,238,996 shares of Class A Common Stock, with prices ranging from $28.35 to $30.08 per share. Despite the sales, Bertolini still holds 7,751,570 shares, while the stock has seen a 98% surge in the past six months and is considered slightly overvalued by InvestingPro.
Oscar Health CEO Bertolini sells $35.7 million in company stock By Investing.com
Oscar Health CEO Mark T Bertolini sold approximately $35.7 million worth of company stock through multiple transactions on June 29 and June 30, 2026. These sales, conducted to cover tax withholding obligations from vested performance stock units, involved 1,238,996 shares at weighted average prices between $28.35 and $30.08. Following these transactions, Bertolini retains direct ownership of 7,751,570 shares, while the company's stock has shown significant recent growth and positive analyst upgrades.
Oscar Health CEO Bertolini sells $35.7 million in company stock By Investing.com
Oscar Health CEO Mark T Bertolini sold approximately $35.7 million worth of company stock through several transactions on June 29 and June 30, 2026. These sales, executed to cover tax withholding obligations from vested performance stock units, involved 1,238,996 shares of Class A Common Stock. Following these transactions, Bertolini still directly holds over 7.7 million shares, amidst recent analyst upgrades and strategic company developments.
Tax-driven Oscar Health (OSCR) CEO sale of 1.24M shares under 10b5-1
Oscar Health CEO Mark T. Bertolini sold 1,238,996 shares of Class A Common Stock between June 29-30, 2026, generating approximately $35.77 million. These sales were reportedly made to cover tax withholding obligations related to vested performance stock units and were executed under a pre-arranged Rule 10b5-1 plan. Following these transactions, Bertolini still directly holds 7,751,570 shares, indicating a tax-driven liquidation rather than a change in investment outlook.
Oscar Health director Mario Schlosser sells $30.18m in stock
Oscar Health director Mario Schlosser sold Class A common stock worth approximately $30.18 million on June 23, 2026, through a Rule 10b5-1 trading plan. The sales involved both direct holdings and shares held indirectly via family trusts, following his acquisition of shares through Class B common stock conversion and option exercises. These transactions occurred amidst Oscar Health's volatile stock performance and recent analyst upgrades, and a transition in Mr. Schlosser's role within the company.
Form 4 Oscar Health Inc For: 30 June By Investing.com
This article announces the filing of Form 4 for Oscar Health Inc. for the period ending June 30. It is a brief corporate notice published by Investing.com. The content itself does not provide details of the Form 4 filing but serves as an announcement for its availability.
Oscar Health (NYSE: OSCR) to reaffirm 2026 outlook at GS event
Oscar Health, Inc. (NYSE: OSCR) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. During this event, the company plans to provide a business update and reaffirm its full-year 2026 financial guidance, which was initially issued on February 10, 2026. A live audio webcast will be available on Oscar Health's investor relations website, with a replay accessible for approximately 90 days.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock
Oscar Health CEO Mark Bertolini sold over 1.2 million shares of Class A Common Stock for approximately $34.9 million on June 25 and 26, 2026. These sales were primarily to cover tax obligations related to vested performance and restricted stock units and were conducted under a Rule 10b5-1 trading plan. Despite the sale, Bertolini still directly holds nearly 9 million shares, and the company has recently seen positive analyst upgrades and strategic changes.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock
Oscar Health CEO Mark Bertolini sold over $34.9 million worth of Class A Common Stock across multiple transactions on June 25 and June 26, 2026. These sales were conducted to cover tax withholding obligations related to vested performance and restricted stock units, under a pre-established Rule 10b5-1 trading plan. Despite the sale, Bertolini still holds a significant number of shares, and analysts expect the health insurance company to become profitable this year, with several recent upgrades to its stock rating.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock
Oscar Health CEO Mark T. Bertolini sold approximately $34.9 million worth of company stock across June 25 and June 26, 2026, to cover tax withholding obligations from vested performance and restricted stock units. This sale, executed under a Rule 10b5-1 trading plan, occurred near the stock's 52-week high after shares surged 105% in six months. Following the transactions, Bertolini retains 8,990,566 shares, as the health insurance company, valued at $8.8 billion, anticipates profitability this year.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock By Investing.com
Oscar Health CEO Mark T. Bertolini sold over $34.9 million in company stock across multiple transactions on June 25 and June 26, 2026. The sales were conducted to cover tax obligations related to vested performance and restricted stock units, under a pre-established trading plan. Following these sales, Bertolini still directly holds nearly 9 million shares, and the company, valued at $8.8 billion, is anticipated to become profitable this year.
Oscar Health (OSCR) CEO Mark Bertolini sells 1.2M shares for tax obligations
Oscar Health CEO Mark T. Bertolini sold 1,206,310 shares of Class A common stock for approximately $34.91 million on June 25-26, 2026. These sales were pre-planned under a Rule 10b5-1 instruction letter and were conducted to satisfy tax withholding obligations related to vested performance and restricted stock units. Following these transactions, Bertolini retains a significant stake, holding at least 8,990,566 shares of Class A common stock.
Oscar Health director Mario Schlosser sells $30.18m in stock By Investing.com
Oscar Health director Mario Schlosser sold over $30 million worth of Class A Common Stock on June 23, 2026, through both direct and indirect sales under a Rule 10b5-1 trading plan. Despite the significant sale near the stock's 52-week high, the company's shares had recently surged by 95%, with InvestingPro analysis suggesting they remain slightly undervalued. Schlosser also acquired a similar number of shares through the conversion of Class B Common Stock, and the company has seen recent upgrades from analysts and changes in his executive role.
Oscar Health CEO Mark Bertolini sells $34.9m in company stock
Oscar Health CEO Mark T. Bertolini sold over 1.2 million shares of the company's Class A Common Stock for approximately $34.9 million across two days, prompted by tax withholding obligations related to vested stock units. These sales, conducted under a Rule 10b5-1 trading plan, occurred near the stock's 52-week high after a significant 105% surge in six months. Following the transactions, Bertolini retains a substantial holding of over 8.9 million shares, as Oscar Health, valued at $8.8 billion, is anticipated to become profitable this year with strong analyst forecasts and recent upgrades from Barclays and Wells Fargo.
Liquidity Mapping Around (OSCR) Price Events
This article analyzes Oscar Health Inc. Class A (NASDAQ: OSCR) using AI models to provide institutional trading strategies. Key findings indicate strong near- and mid-term sentiment, compelling upside potential due to the absence of resistance levels above the current price, and offers detailed entry and exit points for various risk profiles. It presents specific strategies including a Position Trading Strategy, Momentum Breakout Strategy, and Risk Hedging Strategy with detailed target and stop-loss levels.
Oscar Health (NYSE: OSCR) director sells shares after large option exercise
Oscar Health director Mario Schlosser sold 1,027,500 Class A common shares across several family dynasty trusts and his direct holdings. Concurrently, he exercised a stock option for 660,000 Class B shares at $9.75 and converted other Class B shares, acquiring a total of 2,347,500 shares via derivatives. These transactions were executed under a Rule 10b5-1 trading plan adopted on March 24, 2026.
Form 4 Oscar Health Inc For: 25 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Oscar Health Inc. on June 25. Form 4 filings disclose changes in beneficial ownership of a company's securities, often indicating insider transactions. The article provides the title and source but no further details about the specific contents of the Form 4.
Oscar Health director Mario Schlosser sells $30.18m in stock
Oscar Health director Mario Schlosser sold 1,026,500 shares of Class A Common Stock for approximately $30.18 million on June 23, 2026, executed via a Rule 10b5-1 trading plan. Despite the sale occurring near the stock's 52-week high and a 95% surge over six months, InvestingPro suggests the stock remains slightly undervalued. Concurrently, Schlosser acquired 1,027,500 shares through conversion of Class B stock, while recent analyst upgrades and strategic adjustments, including his transition to an advisor role, have marked other notable developments for Oscar Health.
Form 4 Oscar Health Inc For: 25 June By Investing.com
This article reports on a Form 4 filing by Oscar Health Inc. for June 25, 2026. It mentions the company's stock symbol OSCR, which saw a 3.91% increase. The content is brief and primarily serves as an announcement for the financial filing.
Oscar Health, Inc. Class A Actuals & Estimates (NYSE:OSCR)
This article provides an overview of Oscar Health, Inc. (NYSE: OSCR) stock performance, forecasts, and key financial data. It highlights recent stock price movements, analyst price targets ranging from $13.00 to $35.00, and historical highs and lows. The content also delves into recent earnings, revenue figures, market capitalization, and upcoming earnings dates for OSCR.
Oscar Health director Mario Schlosser sells $30.18m in stock By Investing.com
Oscar Health director Mario Schlosser sold over $30.18 million worth of Class A Common Stock on June 23, 2026, through direct sales and family trusts. These transactions occurred after a significant 95% surge in Oscar Health's shares, near their 52-week high, yet InvestingPro analysis suggests the stock remains slightly undervalued. Schlosser also acquired 1,027,500 shares through the conversion of Class B Common Stock, and the sale was executed under a Rule 10b5-1 trading plan.
Form 4 Oscar Health Inc For: 25 June By Investing.com
This article announces the filing of a Form 4 for Oscar Health Inc. on June 25th. Form 4s disclose transactions made by company insiders, but the article does not provide specific details about the transactions. It suggests that readers might find more detailed information within the Investing.com platform.
Oscar Health director Mario Schlosser sells $30.18m in stock By Investing.com
Oscar Health director Mario Schlosser sold approximately $30.18 million worth of the company's Class A Common Stock on June 23, 2026. The sales were conducted through a Rule 10b5-1 trading plan and occurred as the stock neared its 52-week high after a significant rally. Despite the sale, InvestingPro analysis suggests the stock remains slightly undervalued, and recent analyst upgrades further highlight the company's positive trajectory.
This Analyst Just Upgraded Oscar Health Stock. Here's Why.
Wells Fargo upgraded Oscar Health (OSCR) from “Underweight” to “Equal Weight” and nearly doubled its price target to $20, driven by increased confidence in the health insurance exchange market's trajectory for 2026. The upgrade acknowledges significant medical loss ratio improvement in the industry and Oscar Health's strong Q1 results, which surpassed analyst consensus. However, the firm maintains a cautious outlook due to limited visibility beyond 2026, a risk factor that could temper future multiple expansion.
Why (OSCR) Price Action Is Critical for Tactical Trading
This article analyzes Oscar Health Inc. Class A (NASDAQ: OSCR) stock performance, highlighting that if near and mid-term strong sentiment holds, it could extend to the long term. It identifies compelling upside potential due to the absence of resistance levels above the current price. The analysis includes institutional trading strategies, multi-timeframe signal analysis, and AI-generated signals for traders.
Oscar Health shareholders back board, pay and auditor
Oscar Health shareholders recently approved the election of eight directors, the compensation for named executive officers, and the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2026. This indicates strong support for the current board, executive pay practices, and financial oversight. An analyst rating suggests a "Hold" with a $30 price target, while TipRanks' AI Analyst, Spark, rates OSCR as "Outperform" due to improving financial quality and technical momentum.
Oscar Health, Inc. (OSCR) Stock Declines While Market Improves: Some Information for Investors
Oscar Health, Inc. (OSCR) stock declined by 2.25% in a recent trading session, underperforming the broader market despite a strong monthly gain of 24.88%. Investors are anticipating the company's upcoming earnings report, with expectations of significant EPS and revenue growth year-over-year. The stock currently holds a Zacks Rank #3 (Hold) and has a Forward P/E ratio of 61.51, which is a premium compared to its industry.
Oscar Health shareholders back board, pay and auditor
Oscar Health shareholders re-elected all eight directors, approved executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor at their 2026 Annual Meeting. This indicates strong support for the current leadership, pay practices, and financial oversight. An AI analyst from TipRanks rates OSCR as an "Outperform" due to improving financial quality and technical momentum.
Oscar Health (NYSE: OSCR) 2026 vote backs directors, pay and auditor
Oscar Health, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected eight directors to serve until the 2027 Annual Meeting. They also approved the compensation of named executive officers in an advisory vote and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026. The meeting achieved a quorum with over 820 million votes represented, reflecting strong shareholder participation and support for the proposals.
Director at Oscar Health (NYSE: OSCR) awarded 8,475 RSUs
Oscar Health director Laura W. Lang was granted 8,475 restricted stock units (RSUs) of Class A common stock at no cash cost. These RSUs vest on the earlier of one year from the grant date or the next annual stockholder meeting, contingent on continued service. Following this award, Lang's direct holdings in Oscar Health total 82,840 shares.
